{"product_id":"ntla-vrio-analysis","title":"Intellia Therapeutics, Inc. (NTLA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Intellia Therapeutics, Inc. (NTLA)'s market dominance with this laser-focused VRIO analysis. We distill the findings from \u0026amp;O4\u0026amp; to show you exactly where their true, sustainable competitive advantage lies - or where it's missing. Read on to see the complete breakdown of their Value, Rarity, Inimitability, and Organization.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIntellia Therapeutics, Inc. (NTLA) - VRIO Analysis: 1. Proprietary In Vivo CRISPR\/Cas9 Platform (LNP Delivery)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core engine of Intellia Therapeutics, Inc. right now - their in vivo CRISPR\/Cas9 platform using Lipid Nanoparticle (LNP) delivery. This technology is what underpins their two late-stage bets, lonvo-z for hereditary angioedema (HAE) and nex-z for ATTR amyloidosis. Despite the recent FDA clinical hold on nex-z in November 2025, the platform’s capability to deliver a single-dose, potentially curative edit inside the body is the source of all near-term value.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Curative Potential and Pipeline Engine\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe platform’s value rests on its ability to perform precise, single-dose gene editing directly inside the body (in vivo). This is the mechanism for potentially curative treatments for genetic diseases like HAE and ATTR amyloidosis. The company’s strategic focus in 2025 was entirely built around this, prioritizing lonvo-z and nex-z, which is reflected in their operational structure and the $94.7 million in Research and Development expenses reported for Q3 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Specialized Delivery System\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific combination of a proven CRISPR system with proprietary Liver-directed Lipid Nanoparticle (LNP) delivery is what makes this rare in the current biotech landscape. While competitors are advancing, Intellia’s specific LNP formulation, like the one in lonvo-z, is a highly specialized asset. For context, the company is funding operations into mid-2027 with $669.9 million in cash as of September 30, 2025, giving them the runway to defend this specialized lead.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Deep Know-How Barrier\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReplicating this is tough. The specific LNP technology and the hard-won know-how to apply it effectively in vivo are difficult and time-consuming for rivals to copy. It’s not just the components; it’s the execution. Even as of late 2025, new entrants are still benchmarking against components like LP-01, which is part of lonvo-z, showing the established nature of Intellia’s work.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Focused Execution\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOrganizationally, Intellia Therapeutics, Inc. is structured to maximize this platform. Their entire strategic focus in 2025 was built around leveraging this for lonvo-z and nex-z, even leading to a workforce reduction of approximately 27% to focus resources. They are actively building commercial readiness, aiming for a U.S. launch for lonvo-z in 1H 2027, showing clear internal alignment around the platform’s outputs.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment for this platform:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eScore (Implied)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh (Potential Cure)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eHigh (Proprietary LNP\/CRISPR Combo)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh (Difficult to Replicate Know-How)\u003c\/td\u003e\n\u003ctd\u003eNo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh (Strategic Focus \u0026amp; Cash Runway)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSustained Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the regulatory risk, like the recent clinical hold, which tests the Organization component against external shocks. Still, the platform itself remains the key differentiator.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eIntellia Therapeutics, Inc. (NTLA) - VRIO Analysis: 2. Late-Stage Clinical Assets (NTLA-2002 and nex-z)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e These two programs, lonvoguran ziclumeran (NTLA-2002) for HAE and nexiguran ziclumeran (nex-z) for ATTR amyloidosis, represent the most direct path to near-term revenue and market disruption.\u003c\/p\u003e\n\u003cp\u003eNTLA-2002 Phase 2 data (cut-off April 4, 2024) showed a single \u003cstrong\u003e50 mg\u003c\/strong\u003e dose resulted in a 77% mean monthly HAE attack rate reduction during weeks 1-16 versus placebo, with 8 out of 11 patients achieving a complete response (no attacks) through a median follow-up of 8 months. The Phase 3 HAELO study completed enrollment in September. Nex-z (nexiguran ziclumeran) is advancing with two Phase 3 trials: MAGNITUDE (ATTR-CM) and MAGNITUDE-2 (ATTRv-PN). The MAGNITUDE-2 trial will enroll 50 patients randomized one-to-one to a single 55 milligram infusion of nex-z or placebo. The selection of the 55 mg dose for nex-z Phase 3 aligns with the 55 mg dose selected for NTLA-2001 (predecessor) Phase 3, which showed a 93% mean serum TTR reduction sustained through six months in one cohort.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While other companies have CRISPR assets, having two distinct, wholly-owned in vivo assets in Phase 3 is a strong position. The list of CRISPR companies with Phase 3 active clinical trials includes 14 entities.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. Clinical data and regulatory filings are public, but the specific data package for these two assets is unique to Intellia Therapeutics.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The 2025 reorganization specifically cut other programs to focus all execution on these two, showing clear management alignment. Cash, cash equivalents, and marketable securities were $669.9 million as of September 30, 2025, with the runway extended into mid-2027 following restructuring initiatives implemented in early 2025. Research and development (R\u0026amp;D) expenses decreased to $94.7 million in Q3 2025 from $123.4 million in Q3 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The advantage will shift to sustained only upon successful commercialization.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eNTLA-2002 (HAE)\u003c\/th\u003e\n\u003cth\u003enex-z (ATTR Amyloidosis)\u003c\/th\u003e\n\u003cth\u003eFinancial\/Organizational Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment Stage\u003c\/td\u003e\n\u003ctd\u003ePhase 3 (HAELO study enrolling)\u003c\/td\u003e\n\u003ctd\u003ePhase 3 (MAGNITUDE and MAGNITUDE-2)\u003c\/td\u003e\n\u003ctd\u003eCash on Hand (Sept 30, 2025): \u003cstrong\u003e$669.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Dosing\/Cohort Size\u003c\/td\u003e\n\u003ctd\u003e50 mg dose showed 8\/11 complete response\u003c\/td\u003e\n\u003ctd\u003e55 mg fixed dose selected for MAGNITUDE-2\u003c\/td\u003e\n\u003ctd\u003eCash Runway: Extended into \u003cstrong\u003emid-2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Efficacy Data Point\u003c\/td\u003e\n\u003ctd\u003e81% mean attack rate reduction (weeks 5-16, 50mg cohort)\u003c\/td\u003e\n\u003ctd\u003e93% mean serum TTR reduction sustained through \u003cstrong\u003esix months\u003c\/strong\u003e (NTLA-2001 1.0 mg\/kg)\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expense (Q3 2025): \u003cstrong\u003e$94.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Timeline\/Endpoint\u003c\/td\u003e\n\u003ctd\u003eTop-line data expected by \u003cstrong\u003emid-2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePrimary endpoint: mNIS+7 at \u003cstrong\u003emonth 18\u003c\/strong\u003e (MAGNITUDE-2)\u003c\/td\u003e\n\u003ctd\u003eNet Loss (Q3 2025): \u003cstrong\u003e$(101.3 million)\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003eNTLA-2002 Phase 2 complete response patients were attack-free for a median of \u003cstrong\u003e8 months\u003c\/strong\u003e through latest follow-up.\u003c\/li\u003e\n\u003cli\u003eThe NTLA-2001 Phase 1 study included 65 patients reported as of May 11, 2023.\u003c\/li\u003e\n\u003cli\u003eThe 2025 restructuring initiatives resulted in a year-over-year decline in GAAP operating expenses of at least 10% expected.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIntellia Therapeutics, Inc. (NTLA) - VRIO Analysis: 3. Intellectual Property Portfolio (CRISPR\/Cas9 Patents)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the legal foundation to develop and commercialize their gene-editing therapies, blocking competitors from using similar foundational technology for human therapeutics. Intellia holds an \u003cstrong\u003eexclusive license\u003c\/strong\u003e to use the CVC (UC, Vienna, Charpentier) CRISPR\/Cas9 IP estate for the development and commercialization of \u003cstrong\u003ehuman therapeutics\u003c\/strong\u003e, excluding antibacterial and antifungal applications.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Many gene-editing firms have IP, but Intellia Therapeutics holds rights to key components, including a co-owned worldwide patent portfolio. The company's IP portfolio includes foundational filings accessed via licenses from entities including Caribou and Novartis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Patents offer legal protection, making direct imitation impossible without licensing. The company's internally developed portfolio, if issued, would expire no earlier than \u003cstrong\u003e2036\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company actively intends to expand and protect this portfolio as a core asset. The company also protects its brand assets, as \u003cstrong\u003eIntellia Therapeutics and the Intellia Therapeutics logo are registered trademarks\u003c\/strong\u003e with the U.S. Patent \u0026amp; Trademark Offce.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Patents provide a legally enforced barrier to entry. The value derived from this IP is evidenced by significant collaboration structures.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Metric Category\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eAssociated Value\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternally\/Jointly Owned Patent Families\u003c\/td\u003e\n\u003ctd\u003eNumber of families filed since 2015\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOver 70\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternal Portfolio Patent Expiration (Earliest)\u003c\/td\u003e\n\u003ctd\u003eProjected Expiration Year\u003c\/td\u003e\n\u003ctd\u003eNo earlier than \u003cstrong\u003e2036\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Licensing\/Collaboration Potential (ONK)\u003c\/td\u003e\n\u003ctd\u003eTotal Potential Milestone Payments\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$920 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Licensing\/Collaboration Potential (Regeneron)\u003c\/td\u003e\n\u003ctd\u003eTotal Potential Milestone Payments\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$320 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistered Assets\u003c\/td\u003e\n\u003ctd\u003eTrademark Status\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eRegistered\u003c\/strong\u003e with the U.S. Patent \u0026amp; Trademark Offce\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe IP portfolio encompasses:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFoundational filings on the use of CRISPR\/Cas9 systems for genome editing.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eImprovement modifications of these CRISPR systems, including base editor and DNA writing technologies.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eLipid Nanoparticle (LNP) technologies for delivery.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCell expansion technology relevant to stem cell-based therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIntellia Therapeutics, Inc. (NTLA) - VRIO Analysis: 4. Strategic Collaboration with Regeneron Pharmaceuticals, Inc.\n\u003c\/h2\u003e\n\n\u003cp\u003e\nh\u0026gt;Value\n\u003c\/p\u003e\n\u003cp\u003e\nProvides shared risk, access to external expertise, and co-development funding for the ATTR amyloidosis program (nex-z), which is a major, complex indication.\n\u003c\/p\u003e\n\n\u003cp\u003e\nh\u0026gt;Rarity\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. Strategic pharma partnerships are common, but this specific co-development agreement is unique to Intellia Therapeutics' ATTR assets.\n\u003c\/p\u003e\n\n\u003cp\u003e\nh\u0026gt;Imitability\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. Competitors can seek similar deals, but the terms and existing relationship are not easily copied.\n\u003c\/p\u003e\n\n\u003cp\u003e\nh\u0026gt;Organization\n\u003c\/p\u003e\n\u003cp\u003e\nHigh. Collaboration revenue was \u003cstrong\u003e$13.8 million\u003c\/strong\u003e in Q3 2025, showing active financial engagement.\n\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eCollaboration revenue for the first nine months of 2025 was \u003cstrong\u003e$45 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRegeneron shares approximately \u003cstrong\u003e25%\u003c\/strong\u003e of worldwide development costs and commercial profits for the ATTR program.\u003c\/li\u003e\n\u003cli\u003eThe MAGNITUDE Phase 3 trial for ATTR-CM has more than \u003cstrong\u003e650 patients\u003c\/strong\u003e currently enrolled.\u003c\/li\u003e\n\u003cli\u003eThe FDA placed a clinical hold on the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nex-z on \u003cstrong\u003eOctober 29, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\nh\u0026gt;Competitive Advantage\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. The value is tied to the success and continuation of the specific co-development agreement.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\/Event\u003c\/th\u003e\n\u003cth\u003eAmount\/Date\u003c\/th\u003e\n\u003cth\u003eProgram\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Collaboration Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCost reimbursements related to Regeneron collaboration.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Nine Months 2025 Collaboration Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$45 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRelated to collaboration with Regeneron (REGN) on the ATTR program.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOriginal 2016 Upfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$75 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFrom initial licensing and collaboration agreement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2020 Expansion Upfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUpfront cash from collaboration expansion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2020 Equity Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAt \u003cstrong\u003e$32.42\u003c\/strong\u003e per share as part of collaboration expansion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2024 One-Time Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRelated to technology collaboration.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATTR Profit\/Cost Sharing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRegeneron's share of worldwide development costs and commercial profits.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eIntellia Therapeutics, Inc. (NTLA) - VRIO Analysis: 5. Financial Runway and Focused Capital Allocation\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The company ended Q3 2025 with approximately \u003cstrong\u003e$669.9 million\u003c\/strong\u003e in cash, cash equivalents and marketable securities. This balance, combined with restructuring initiatives implemented in early 2025, enables the extension of the cash runway into \u003cstrong\u003emid-2027\u003c\/strong\u003e, covering critical milestones like the anticipated Biologics License Application (BLA) submission for NTLA-2002 in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Date\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$669.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities (Q4 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$861.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-end 2024 balance.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$707.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eATM Facility Raise (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$115 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRaised during the third quarter of 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$101.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to $135.7 million in the prior year quarter.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$94.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecrease of $28.7 million from the prior year quarter.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A Expenses (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSame as the prior year quarter.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. While many clinical-stage biotechs maintain cash reserves, the specific combination of the current balance and the projected runway extending through the anticipated first commercial launch in the \u003cstrong\u003efirst half of 2027\u003c\/strong\u003e is less common without immediate financing needs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. The extension of the runway is directly tied to organizational discipline, including a net workforce reduction of approximately \u003cstrong\u003e27%\u003c\/strong\u003e over 2025 and an estimated \u003cstrong\u003e$8 million\u003c\/strong\u003e charge incurred primarily in Q1 2025 for the reorganization.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management executed a strategic reorganization in \u003cstrong\u003eearly 2025\u003c\/strong\u003e, discontinuing NTLA-3001 and select research-stage programs to focus resources, demonstrating a clear organizational commitment to capital efficiency ahead of late-stage milestones.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This financial buffer provides a time-based advantage, specifically covering operations until \u003cstrong\u003emid-2027\u003c\/strong\u003e, which erodes with every quarter of operational expenditure.\u003c\/p\u003e\n\u003cp\u003eKey Operational and Financial Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEnrollment completion for the Phase 3 HAELO study (NTLA-2002) was achieved in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e (Q3 2025).\u003c\/li\u003e\n\u003cli\u003eAnticipated BLA submission for NTLA-2002 in \u003cstrong\u003eH2 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated commercial launch for NTLA-2002 in the U.S. in the \u003cstrong\u003efirst half of 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected year-over-year decline in GAAP operating expenses of at least \u003cstrong\u003e10%\u003c\/strong\u003e for 2025.\u003c\/li\u003e\n\u003cli\u003eCumulative enrollment for the MAGNITUDE study (nex-z) expected to exceed \u003cstrong\u003e550 patients\u003c\/strong\u003e by year-end 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIntellia Therapeutics, Inc. (NTLA) - VRIO Analysis: 6. Deep Scientific\/Clinical Development Experience (Human Capital)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The team's experience is helping set the standard for a new class of medicine, crucial for navigating complex Phase 3 trials and regulatory interactions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many biotechs have smart people, Intellia Therapeutics' specific, long-standing experience in in vivo CRISPR development is a deep, hard-to-hire asset.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. It takes years to build this institutional knowledge and trust with regulators.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. Despite the CSO retiring at the end of 2025, the core team executed on key 2025 milestones, like completing HAELO enrollment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Experience is the hardest asset to buy quickly.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eMetric\/Role\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Development Execution (NTLA-2002\/HAELO)\u003c\/td\u003e\n\u003ctd\u003ePhase 3 Enrollment Completion Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Development Execution (NTLA-2002\/HAELO)\u003c\/td\u003e\n\u003ctd\u003ePhase 3 Enrollment Start Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Development Execution (NTLA-2002\/HAELO)\u003c\/td\u003e\n\u003ctd\u003eNumber of Patients Enrolled (at completion)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOver 60 patients\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Development Execution (nex-z\/MAGNITUDE)\u003c\/td\u003e\n\u003ctd\u003eATTR-CM Enrollment (as of Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e650 patients\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Development Execution (nex-z\/MAGNITUDE-2)\u003c\/td\u003e\n\u003ctd\u003eATTRv-PN Enrollment (as of Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e47 patients\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Pathway (NTLA-2002)\u003c\/td\u003e\n\u003ctd\u003eTopline Data Expected\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMid-2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Pathway (NTLA-2002)\u003c\/td\u003e\n\u003ctd\u003eBLA Submission Planned\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSecond half of 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Pathway (NTLA-2002)\u003c\/td\u003e\n\u003ctd\u003eAnticipated U.S. Launch\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFirst half of 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman Capital Transition (CSO)\u003c\/td\u003e\n\u003ctd\u003eCSO Retirement Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecember 31, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman Capital Transition (CSO)\u003c\/td\u003e\n\u003ctd\u003eNew CSO Effective Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 13, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHuman Capital Transition (CMO)\u003c\/td\u003e\n\u003ctd\u003eCMO Retirement Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAugust 7, 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganizational Efficiency\u003c\/td\u003e\n\u003ctd\u003eNet Workforce Reduction (2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e27%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Runway\u003c\/td\u003e\n\u003ctd\u003eCash Runway Projection (based on Q4 2024)\u003c\/td\u003e\n\u003ctd\u003eInto the \u003cstrong\u003efirst half of 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Runway\u003c\/td\u003e\n\u003ctd\u003eCash Position (as of Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$669.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance (Historical)\u003c\/td\u003e\n\u003ctd\u003eOperating Margin (at one point)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-968.69%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe scientific leadership has a history of navigating complex development stages:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCEO John Leonard, M.D., has experience from AbbVie, including leading breakthrough medicines through discovery, development, and launch into blockbuster drugs following a 30-year career in pharmaceutical R\u0026amp;D.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company announced its first human clinical data for an \u003cem\u003ein vivo\u003c\/em\u003e gene editing therapeutic candidate in June 2021.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company ended Q4 2024 with approximately \u003cstrong\u003e$862 million\u003c\/strong\u003e in cash, cash equivalents and investments.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCollaboration Revenue for Q2 2025 was \u003cstrong\u003e$14.2 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$6.9 million\u003c\/strong\u003e during Q2 2024.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eIn Q3 2025, the company raised \u003cstrong\u003e$114.5 million\u003c\/strong\u003e of net equity proceeds from its ATM program.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIntellia Therapeutics, Inc. (NTLA) - VRIO Analysis: 7. Proprietary Manufacturing Facility (Waltham, MA)\n\u003c\/h2\u003e\n\u003cp\u003eThe proprietary manufacturing facility located in Waltham, Massachusetts, is a key component of Intellia Therapeutics' operational strategy for its CRISPR-based therapies.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eA dedicated, state-of-the-art Good Manufacturing Practice (GMP) facility supports preclinical through commercial supply, reducing reliance on third parties for key components. This facility is designed to support manufacturing from \u003cstrong\u003epreclinical\u003c\/strong\u003e through \u003cstrong\u003ecommercial production\u003c\/strong\u003e upon regulatory approval for key components of Intellia's investigational therapies.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate. Having in-house GMP capacity for novel modalities like Lipid Nanoparticle (LNP)-delivered CRISPR is a significant advantage over relying solely on Contract Manufacturing Organizations (CMOs). The company's existing footprint included \u003cstrong\u003e65,000 square feet\u003c\/strong\u003e of office and lab space, with an additional \u003cstrong\u003e60,000 square feet\u003c\/strong\u003e leased in two other Cambridge facilities prior to this expansion.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHigh. Building and validating a new GMP facility takes years and massive capital outlay. The CFO noted that the long-term lease agreement provided Intellia with greater manufacturing flexibility and only a \u003cstrong\u003emodest financial upfront requirement\u003c\/strong\u003e compared with building the facility from the ground up.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh. The facility was built to support commercial readiness, aligning with the strategic pivot toward commercialization. The new facility is customized for Intellia's requirements and is being constructed and managed by Alexandria Real Estate Equities, L.P.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained. Control over supply chain quality and volume is critical for a launch. The facility is expected to be operational in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSpecification\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocation\u003c\/td\u003e\n\u003ctd\u003eWaltham, Massachusetts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSize\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e140,000 square feet\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance Standard\u003c\/td\u003e\n\u003ctd\u003eGood Manufacturing Practice (GMP) compliant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Target Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManagement\/Structure\u003c\/td\u003e\n\u003ctd\u003eConstructed and managed by Alexandria Real Estate Equities under a lease agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe facility supports the manufacturing of key components for Intellia's CRISPR-based investigational therapies.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eThe new Waltham facility is intended to provide capacity and capabilities in support of Intellia's \u003cstrong\u003eexpanding pipeline\u003c\/strong\u003e and commercial readiness.\u003c\/li\u003e\n\u003cli\u003eFor comparison, a separate operating lease agreement for approximately \u003cstrong\u003e38,000 square feet\u003c\/strong\u003e of office and laboratory space in Cambridge had a base rent of \u003cstrong\u003e$130.00 per square foot per year\u003c\/strong\u003e during the first year of its term, subject to scheduled \u003cstrong\u003e3% annual increases\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIntellia Therapeutics, Inc. (NTLA) - VRIO Analysis: 8. Advanced In Vivo Gene Insertion Technology (e.g., DNA Writing)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Expanding beyond simple gene knockout to more complex edits like gene insertion opens up a much wider range of treatable diseases beyond the current pipeline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Novel editing techniques like DNA writing are at the very forefront of the science and not widely deployed yet.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Cutting-edge R\u0026amp;D that requires specialized scientific breakthroughs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is still in the research phase for these, but they are a core part of their long-term platform expansion.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Being a leader in the next generation of editing tools secures future optionality.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDemonstrated \u003cstrong\u003e87%\u003c\/strong\u003e average reduction in TTR levels in higher dose group for NTLA-2001 in Phase 1 trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eAcquisition of Rewrite Therapeutics for \u003cstrong\u003e$45 million\u003c\/strong\u003e upfront, with up to \u003cstrong\u003e$155 million\u003c\/strong\u003e more in potential milestones for DNA writing technology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eAcquisition cost reflects the high barrier to replicate the 'write' technology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eLeveraging platform through partnerships: Regeneron deal included \u003cstrong\u003e$75 million\u003c\/strong\u003e upfront payment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePlatform advancements include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003ePreclinical data demonstrated proof-of-concept for in vivo gene insertion and knockout for alpha-1 antitrypsin deficiency (AATD) in non-human primates.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe acquisition of Rewrite Therapeutics included potential milestone payments of up to \u003cstrong\u003e$155 million\u003c\/strong\u003e in cash and stock.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eStrategic collaborations include a deal with ONK Therapeutics potentially yielding up to \u003cstrong\u003e$184 million\u003c\/strong\u003e per product in milestone payments.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe Regeneron collaboration involved an upfront payment of \u003cstrong\u003e$75 million\u003c\/strong\u003e and an agreement for Regeneron to invest up to \u003cstrong\u003e$50 million\u003c\/strong\u003e in Intellia's next equity financing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eIntellia Therapeutics, Inc. (NTLA) - VRIO Analysis: 9. Commercial Readiness Buildout\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Proactive steps, such as planning the 'complete buildout of the commercial leadership team by second half of 2025,' position the company to launch NTLA-2002 quickly upon approval. The company expects a U.S. launch for NTLA-2002 in 2027 or 1H 2027.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. All late-stage companies execute this, but Intellia Therapeutics is targeting an early launch timeline of 1H 2027 for NTLA-2002.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors will follow a similar playbook, but timing relative to clinical data and regulatory submission is critical.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The focus on medical education and payer discussions in 2025 demonstrates organization for the R\u0026amp;D to sales transition.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This advantage is relevant until the first commercial launch is executed.\u003c\/p\u003e\n\n\u003cp\u003eThe following details key commercial and financial milestones related to readiness:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eComplete buildout of the commercial leadership team by second half of 2025.\u003c\/li\u003e\n\u003cli\u003ePhase 3 HAELO study enrollment for NTLA-2002 completed in September 2025.\u003c\/li\u003e\n\u003cli\u003eBLA submission planned for second half of 2026 for NTLA-2002.\u003c\/li\u003e\n\u003cli\u003eInitiate pre-approval information exchange with payers in 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: Projected Cash Burn Rate Analysis (Based on Latest Available Data - Q3 2025)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe cash burn rate is proxied by the quarterly operating expenses, as Q4 2025 actuals are not yet reported. The company's stated cash runway is into mid-2027.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003ctd\u003eCitation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$669.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Expectation\u003c\/td\u003e\n\u003ctd\u003eInto mid-2027\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development (R\u0026amp;D) Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$94.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral \u0026amp; Administrative (G\u0026amp;A) Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$101.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Equity Proceeds from ATM\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$115 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516219121813,"sku":"ntla-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ntla-vrio-analysis.png?v=1740185360","url":"https:\/\/dcf-analysis.com\/products\/ntla-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}